Equities Analysts Offer Predictions for USNA Q4 Earnings

USANA Health Sciences, Inc. (NYSE:USNA) – Investment analysts at DA Davidson issued their Q4 2024 EPS estimates for shares of USANA Health Sciences in a research note issued to investors on Wednesday, October 23rd. DA Davidson analyst L. Weiser expects that the company will earn $0.49 per share for the quarter. DA Davidson has a “Neutral” rating and a $35.00 price target on the stock. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.50 per share.

USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, October 22nd. The company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.07. USANA Health Sciences had a return on equity of 10.80% and a net margin of 6.30%. The firm had revenue of $200.22 million during the quarter, compared to analysts’ expectations of $208.45 million. During the same quarter last year, the business posted $0.59 earnings per share.

Separately, StockNews.com cut shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 24th.

USANA Health Sciences Price Performance

USANA Health Sciences stock opened at $37.81 on Friday. USANA Health Sciences has a 1 year low of $34.15 and a 1 year high of $54.81. The firm’s 50 day moving average price is $37.96 and its 200-day moving average price is $42.51. The stock has a market cap of $720.28 million, a P/E ratio of 13.36, a PEG ratio of 1.15 and a beta of 0.89.

Insider Buying and Selling at USANA Health Sciences

In other news, insider Paul A. Jones sold 6,266 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total transaction of $240,489.08. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other USANA Health Sciences news, insider Paul A. Jones sold 6,266 shares of USANA Health Sciences stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total value of $240,489.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gilbert A. Fuller sold 674 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $39.69, for a total transaction of $26,751.06. The disclosure for this sale can be found here. Insiders sold 7,940 shares of company stock worth $311,670 in the last quarter. 0.33% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On USANA Health Sciences

Institutional investors have recently modified their holdings of the stock. DGS Capital Management LLC raised its holdings in USANA Health Sciences by 61.8% during the 1st quarter. DGS Capital Management LLC now owns 7,258 shares of the company’s stock valued at $352,000 after buying an additional 2,773 shares during the period. BNP Paribas Financial Markets raised its stake in shares of USANA Health Sciences by 18.1% in the first quarter. BNP Paribas Financial Markets now owns 38,820 shares of the company’s stock valued at $1,883,000 after acquiring an additional 5,952 shares during the period. Pzena Investment Management LLC lifted its holdings in shares of USANA Health Sciences by 3.1% in the 1st quarter. Pzena Investment Management LLC now owns 785,344 shares of the company’s stock worth $38,089,000 after acquiring an additional 23,729 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its stake in shares of USANA Health Sciences by 22.7% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 8,430 shares of the company’s stock worth $409,000 after purchasing an additional 1,560 shares during the period. Finally, BOKF NA boosted its stake in shares of USANA Health Sciences by 274.5% during the 1st quarter. BOKF NA now owns 2,771 shares of the company’s stock worth $133,000 after purchasing an additional 2,031 shares during the period. 54.25% of the stock is owned by institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.